ME Stock Recent News

The company, which has launched an investigation into the attack, said Friday it could not yet confirm whether the leaked information is real.

A hacker is advertising millions of "pieces of data" stolen from the family genetics websites 23andMe, according to posts made to an online forum where digital thieves often advertise leaked data.

Shares of 23andMe Holding Co. ME, -4.35% jumped 23% in the extended session Thursday after the genetics and biopharmaceutical company said that the U.S. Food and Drug Administration has cleared it to add more gene variants to the company's direct-to-consumer health reports on genetic risks for certain cancers. The 41 gene variants in question are associated with higher risk for breast, ovarian, prostate, pancreatic, and potentially other cancers, 23andMe said.

510(k) clearance will allow 23andMe to report an additional 41 genetic variants in the BRCA1 and BRCA2 genes that increase risk for breast, ovarian, prostate and pancreatic cancer

AI for drug development is very fashionable in biotech, and for good reason. 23andMe's consumer business could one day provide a bedrock of stability.

The genetics specialist notched a double miss with its latest earnings report. It seems this fiscal year will be worse than its predecessor for headline fundamentals.

23andMe Holding Co. (NASDAQ:ME ) Q1 2024 Results Conference Call August 8, 2023 4:30 PM ET Company Participants Katie Watson - Vice President of Communications Anne Wojcicki - Chief Executive Officer and Co-Founder Joe Selsavage - Interim Chief Financial and Accounting Officer Kenneth Hillan - Chief Therapeutics Officer Conference Call Participants David Lebowitz - Citi Gaurav Goparaju - Berenberg Capital Markets Operator Hello, and welcome to 23andMe's Fiscal Year 2024 First Quarter Financial Results Conference Call. As a reminder, this call is being recorded.

SOUTH SAN FRANCISCO, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fiscal year 2024 (FY2024) first quarter after the market closes on Tuesday, August 8, 2023. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's financial results and report on business progress.

23andMe entered its IPO with two down years on revenue but has since reclaimed low double-digit growth. Throughout this time, however, the company has not made identifiable progress toward profitability on either an accrual or cash basis. It continues to use cash from the IPO for operations. This makes for a hold rating even though it is operating in a significant growth market, consumer genetics testing, that has a CAGR of over 20%.

23andMe Holding Co. (NASDAQ:ME ) Q4 2023 Results Conference Call May 25, 2023 4:30 PM ET Company Participants Maeve Conneighton - Investor Relations at Argo Partners Anne Wojcicki - Chief Executive Officer & Co-Founder Joe Selsavage - Interim Chief Financial Officer & Accounting Officer Kenneth Hillan - Chief Therapeutics Officer Conference Call Participants Daniel Grosslight - Citi Steven Mah - Cowen Operator Hello, and welcome to 23andMe's Fiscal Year 2023 Fourth Quarter and Full Year Financial Results Conference Call. As a reminder, this call is being recorded.